Oct. 5 at 2:42 AM
$CGTX CGTX still appears to have an open possibility for BTD through ongoing discussions with the FDA, likely in the form of a resubmission with additional data after an initial denial. At the same time, Fast Track has either already been submitted or is expected imminently. The likelihood of pursuing both BTD and Fast Track in parallel seems high.
